SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wilske KR, Healey LA. Remodeling the pyramid: a concept whose time has come. J Rheumatol 1989; 16: 5657.
  • 2
    Landewe RBM. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 2003; 48: 15.
  • 3
    Verstappen SMM, Jacobs JWG, Bijlsma JWJ, Heurkens AHM, van Booma-Frankfort C, Jan ter Borg E, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs verus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003; 48: 1797807.
  • 4
    Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [published erratum appears in Lancet 1998;351:220]. Lancet 1997; 350: 30918.
  • 5
    Landewe RB, Boers M, Verhoeven AC, Westhovens R, van De Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 34756.
  • 6
    Van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM, et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. Ann Rheum Dis 2000; 59: 46877.
  • 7
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 158693.
  • 8
    Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 144350.
  • 9
    Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FinRACo trial group. Lancet 1999; 353: 156873.
  • 10
    Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 8948.
  • 11
    Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003; 48: 4653.
  • 12
    Landewe RBM, Boers M, Verhoeven AC, Boonen A, van der Heijde DMFM, van der Linden S. A longitudinal analysis of the relationship between change in DAS28 and change in radiological progression rate [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S175.
  • 13
    Welsing PMJ, Swinkels HL, van Gestel AM, van Riel PLCM. The relation between disease activity and radiologic progression of joint damage in rheumatoid arthritis [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S277.